Panagiotis Prinos appointed as Director of Réseau DePTAQ
ɬÀï·¬, the Institut de recherches cliniques de Montréal (IRCM) and Université de Sherbrooke, partners in the RNA Network for Therapy Development & Production (Réseau DePTAQ), are pleased to announce the appointment of Panagiotis (Takis) Prinos, PhD, as Director of Réseau DePTAQ.
To enhance Quebec’s world-leadership in biomedical and biopharmaceutical research in RNA therapies, Réseau DePTAQ provides academic researchers and industrial partners with a single interface and specialized services for the development and production of RNA therapies through three platforms: the IRCM’s Sidney-Altman RNA Therapeutic Hub, the Therapeutic messenger RNA platform at ɬÀ﷬’s Centre for RNA Sciences, and Sherbrooke University’s RNomic Platform.
As Director, Mr. Prinos will oversee and elevate the Réseau DePTAQ’s service platforms while fostering interdisciplinary collaborations across Quebec and Canada. He will also lead business development and industry liaison efforts.
An accomplished biomedical scientist and strategic manager with over 15 years of experience leading innovative cancer genomics and personalized medicine projects, Mr. Prinos previously served as Team Leader of Epigenetics Cellular Screening at the Structural Genomics Consortium (SGC) at the University of Toronto, and Director of the Phenotypic Platform at L’Université de Sherbrooke. Mr. Prinos’s extensive experience managing cross-functional teams and resources and his skills in building strong stakeholder relationships underscores his unique qualifications for this important position.
Please join us in welcoming him to Réseau DePTAQ!
Réseau DePTAQ is funded by the Government of Quebec and the three partners, as well as by ɬÀï·¬'s DNA to RNA (D2R) research initiative. DePTAQ is one of five strategic initiatives of , Quebec's RNA cluster. Launched by the Ministère de l'Économie, de l'Innovation et de l'Énergie (MEIE), AReNA's mission is to strengthen and raise the profile of the RNA-based therapies industry, and to create a dynamic ecosystem around RNA therapies in Quebec, contributing to its international profile.
Ìý
